Amid a challenging economic environment defined by persistent inflation, rising interest rates, recessionary concerns and falling equity values increasing uncertainty, healthcare and life sciences (HCLS) investors are poised to forge ahead with 60% of respondents indicating they plan to increase their M&A activity in 2023 according to new findings from the 2023 KPMG Healthcare and Life Sciences Investment Outlook.
Nearly half of HCLS respondents expect valuations to drop in 2023 compared to just 14% from the prior year. Most healthcare respondents expect to see decreased valuations in Dx companies and post-acute care while life sciences respondents expect to see the greatest decline in diagnostics manufacturers in the year ahead.
The report features insights from a survey of more than 300 industry executives who provide their perspectives on how evolving market factors and the policy environment may impact investment decisions in 2023. Read more.
